The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The Stelara (Ustekinumab) Market During 2026–2030?
The market size for stelara (ustekinumab) has shown strong expansion in recent years. It is anticipated to increase from $11.85 million in 2025 to $12.54 million in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. The growth observed in the past can be attributed to factors such as the drawbacks of traditional immunosuppressants, the increasing occurrence of autoimmune diseases, robust clinical efficacy information, the common practice of hospital-based biologic administration, and the ongoing need for lasting remission.
The market size for stelara (ustekinumab) is projected to experience robust expansion over the coming years. It will grow to $15.57 million in 2030 at a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast timeframe is attributable to several factors, including an increase in inflammatory bowel disease instances, broadened biologic reimbursement access, patients favoring less frequent dosing schedules, the influence of biosimilar competition, and advancements in biologic delivery devices. Key trends identified for the forecast period encompass an increasing reliance on targeted biologic therapies, a wider range of indications for autoimmune diseases, a move towards long-term maintenance therapies, the increasing use of subcutaneous biologics, and a rise in at-home administration.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp
Which Significant Factors Are Encouraging Growth In The Stelara (Ustekinumab) Market?
An increasing number of individuals diagnosed with psoriasis is projected to drive the expansion of the stelara (ustekinumab) market moving forward. Psoriasis is a persistent autoimmune condition where skin cell regeneration is accelerated, leading to characteristic red, flaky skin patches. This rise in prevalence can be attributed to various factors, including advancements in diagnosis, environmental triggers, genetic susceptibility, and an aging demographic. Stelara (ustekinumab) works by targeting and blocking interleukin-12 and interleukin-23, thereby assisting psoriasis sufferers through effective reduction of inflammation and plaque development, which results in clearer skin and sustained symptom control, ultimately improving their overall quality of life. For instance, according to an August 2024 report by the National Psoriasis Foundation (NPF), a US-based non-profit organization, psoriasis impacts approximately 3% of U.S. adults aged 20 and over, totaling more than 7. million individuals. Additionally, an estimated 600,000 adults in the country are believed to have psoriasis but remain undiagnosed. Consequently, the growing prevalence of psoriasis patients is anticipated to fuel the expansion of the stelara (ustekinumab) market.
What Segment Categories Are Evaluated In The Stelara (Ustekinumab) Market Study?
The stelara (ustekinumab) market covered in this report is segmented –
1) By Indication: Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Other Indications
2) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Pediatric, Adult, Geriatric
What Trends Are Affecting The Growth Of The Stelara (Ustekinumab) Market?
Leading companies in the stelara (ustekinumab) market are actively developing innovative products, such as biosimilars to stelara, aiming to deliver a cost-effective treatment alternative for individuals with chronic inflammatory conditions. Stelara biosimilars are biologically similar medicines crafted to replicate the therapeutic effects of Stelara (Ustekinumab), by targeting IL-12 and IL-23, for treating autoimmune conditions like psoriasis and psoriatic arthritis. For instance, in October 2024, Accord BioPharma Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is distinguished by its extensive indications, providing treatment for adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and ulcerative colitis. Notably, it is also indicated for pediatric patients aged 6 years and older with moderate to severe plaque psoriasis and active psoriatic arthritis, demonstrating its adaptability across various age groups. This broad scope positions IMULDOSA as a significant choice for managing a range of immune-mediated inflammatory diseases.
Who Are The Key Market Participants In The Stelara (Ustekinumab) Market?
Major companies operating in the stelara (ustekinumab) market are Johnson & Johnson
Access The Complete Stelara (Ustekinumab) Market Report:
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-
Which Geographic Region Represents The Largest Stelara (Ustekinumab) Market Share?
North America was the largest region in the stelara (ustekinumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model